ERCC1 and small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1876-1877

  Rossi, Giulio ^a   Nannini, Nazarena ^a   Tiseo, Marcello ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PLATINUM;

CANCER CHEMOTHERAPY; CANCER STAGING; CORRELATION ANALYSIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL;

EID: 78149458450     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f69fb1     Document Type: Letter

References (5)

1. Skov BG, Holm B, Erreboe A, et al. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung. Distribution and impact on survival. J Thorac Oncol 2010;5:453-459.
2. Chiappori AA, Zheng Z, Chen T, et al. Features of potentially predictive biomarkers in chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010;5:484-490.
3. Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009;65: 105-111.
4. Lee HW, Han JH, Kim JH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008;59:95-104.
5. Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing-1 and topoisomerase IIα gene expression in small-cell lung cancer patients treated with platinum and etoposide. A retrospective study. J Thorac Oncol 2008;3:583-589.